Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Operating Lease Liabilities

Operating Lease Liabilities at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$198.23M-7.6%
Cytokinetics logo
CytokineticsCYTK
$102.43M-7.7%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$90.07M+22.4%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$14.27M-21.7%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$17.92M-11.1%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$13.94M+3,323%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Accrued other expenses8,5557,920
Operating lease liability, current portion1,0171,014
Total current liabilities22,54327,370
Operating lease liability, net of current portion2,7762,976
Total liabilities25,31930,346
Commitments and contingencies (see note 5)
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s operating lease liabilities?
Edgewise Therapeutics, Inc. (EWTX) reported operating lease liabilities of $2.78M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
Edgewise Therapeutics, Inc.'s operating lease liabilities decreased by 22.0% year-over-year, from $3.56M to $2.78M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s operating lease liabilities?
Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s operating lease liabilities has grown at a -7.8% compound annual growth rate (CAGR), from $3.8M to $2.98M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Edgewise Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude